The effectiveness of personalized homeopathic treatments for non alcoholic fatty liver disease A study comparing homoeopathic treatment with placebo.

Efficacy of Individualized Homeopathic medicines in Non Alcoholic Fatty Liver Disease A Randomized Placebo Controlled Clinical Trial. - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074404

Enrollment

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Constitutional Homoeopathic medicines: After assessing the totality of symptoms of each patient, consider the most suitable homoeopathic medicinal potency.Potency and repetition of medi

Eligibility

Inclusion criteria

Inclusion criteria: 1.Cases with elevated liver enzymes ALT or AST. 2. Ultrasonography abdomen findings with grade 1& grade 2 fatty liver. 3.Non Alcoholic Male and Female Patients aged between 18-60years. 4. Individuals with present or past history of alcohol consumption in an amount less than a particular level aged between 18-60 years(20 gm/day for males and 10 gm/day for females) of alcohol will be included

Exclusion criteria

Exclusion criteria: 1. Adults who had a heart attack or stroke, or other atherosclerotic disease. 2. Patients diagnosed with diabetics (glycosylated hemoglobin above 6.5%.) 3. Patients diagnosed with moderate and severe hypertension (BP 160/100 mmHg above) 4. Patients with HBsAg positive. 5. Patients with complications of hepatic steatosis like liver cirrhosis, hepatocellular carcinoma. 6. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of individualized homoeopathic medicines relative to a placebo in modifying blood ALT and AST levels and grading of fatty liver in ultrasonography findings in patients with NAFLDs after 15 weeks of study.Timepoint: Each case will be reviewed at 3 weeks interval and followed for a period of minimum 15 weeks. Serum ALT and AST value estimation will be done at an interval of 3 weeks or whenever necessary. Risk for fibrosis will be assessed by calculating fibrosis score FIB-4 index. USG Abdomen will be done at baseline and at final outcome period.	—

Measure

Time frame

To determine the efficacy of individualized homoeopathic medicines relative to a placebo in modifying blood ALT and AST levels and grading of fatty liver in ultrasonography findings in patients with NAFLDs after 15 weeks of study.Timepoint: Each case will be reviewed at 3 weeks interval and followed for a period of minimum 15 weeks. Serum ALT and AST value estimation will be done at an interval of 3 weeks or whenever necessary. Risk for fibrosis will be assessed by calculating fibrosis score FIB-4 index. USG Abdomen will be done at baseline and at final outcome period.

—

Secondary

Measure	Time frame
determine the change in ‘risk for fibrosis’ in patients before and after treatment by FIB-4 index.Timepoint: Changes in the risk for fibrosis will be accessed by FIB-4 index at baseline &15 weeks after treatment.	—

Countries

India

Contacts

Public ContactDr Thara K

Government Homoeopathic Medical College, Karaparamba Kozhikode

drthararaj@gmail.com9745245755

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026